CTLA4 and neoplasm: ICIs include programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, which can restore the immune response against tumor-derived antigens by restoring T-cell activity and promoting the T-cell recognition of tumor-derived antigens [100,101].